Currently out of the existing stock ratings of Michelle Gilson, 64 are a BUY (94.12%), 4 are a HOLD (5.88%).

Michelle Gilson

Work Performance Price Targets & Ratings Chart

Analyst Michelle Gilson, carries an average stock price target met ratio of 46.15% that have a potential upside of 24.24% achieved within 201 days. Previously, Michelle Gilson worked at MORGAN STANLEY, OPPENHEIMER, CANACCORD.

Michelle Gilson’s has documented 131 price targets and ratings displayed on 14 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on VIR, Vir Biotechnology at 11-Jun-2026.

Wall Street Analyst Michelle Gilson

Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 9/16/2016. The price target of $60 was fulfilled within 6 days with a profit of $31.85 (113.14%) receiving and performance score of 188.57.

Average potential price target upside

of $52.64 (41.43%) on ASND (ASCENDIS PHARMA AS).
of $30.79 (68.33%) on SGTX (SIGILON THERAPEUTICS ).
of $28.48 (102.13%) on SRPT (SAREPTA THERAPEUTICS).

ASND Ascendis Pharma AS BMRN Biomarin Pharmaceutical CCXI ChemoCentryx FIXX Homology Medicines SGTX Sigilon Therapeutics SRPT Sarepta Therapeutics STOK Stoke Therapeutics TVTX Travere Therapeutics RTRX Travere Therapeutics AMYT Amryt Pharma Holdings Ltd RZLT Rezolute VIR Vir Biotechnology CLLS Cellectis SA SG Sweetgreen

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Luca Issi (RBC)